证券日报网讯九典制药（300705）8月22日在互动平台回答投资者提问时表示，公司目前的研发进展符 合预期，公司将持续打造"久悦"贴膏品牌，通过先发优势、渠道优势及成本优势等，致力于在经皮给药 领域深化影响力，进一步稳固行业领先地位。 ...

Group 1: Company Overview and Strategy - The company has a complete industrial chain layout, enabling self-production of active pharmaceutical ingredients and key excipients, ensuring product quality while effectively controlling costs [2][5] - The company plans to increase investment in the outpatient market, which has become a new growth engine for performance [2] - The company maintains high investment in R&D to continuously innovate and expand its product line, particularly focusing on the "JiuYue" brand in the transdermal drug delivery field [2][3] Group 2: Market Response and Pricing Strategy - The company will actively respond to the impact of competitor product approvals by optimizing cost structures and enhancing innovation capabilities [2][4] - With the nationwide implementation of centralized drug procurement policies, drug prices are expected to decline, necessitating continuous strategic adjustments by pharmaceutical manufacturers [4] Group 3: Financial Projections - For 2025, the company expects a revenue growth of 10-20% year-on-year, with a similar increase in net profit after deducting non-recurring items [6][7] - The company's operational plans and sales forecasts are subject to market conditions and regulatory environments, indicating significant uncertainty [7] Group 4: M&A Strategy - The company will consider multiple directions for mergers and acquisitions, focusing on targets that align with its development strategy, enhance technological capabilities, and enrich its product pipeline [7]

Market Overview - The transdermal patch industry is experiencing rapid growth due to factors such as an aging population facing chronic pain issues like arthritis and muscle pain, which increases market demand for patch products [2][3] - Public awareness of scientific medication and health management is rising, leading to a preference for convenient and safe external medications like transdermal patches [2][3] Company Advantages - The company benefits from a complete industrial chain, allowing for in-house production of active pharmaceutical ingredients and key excipients, ensuring product quality while controlling costs [3][8] - A comprehensive sales channel system has been established, particularly in the outpatient market, which is a new growth engine for performance [3] - Continuous high investment in R&D enables the company to innovate and expand its product line, enhancing its competitive edge [3][8] Product Strategy - The company is optimistic about the market prospects for its anti-inflammatory and analgesic patches, focusing on OTC channels and leveraging shared sales resources to boost sales [4] - The sales team consists of over 400 personnel, enhancing the company's market reach [5] Marketing and Promotion - Multi-channel collaboration strategies are employed for OTC promotion, integrating online and offline channels, including partnerships with pharmacies and e-commerce platforms [6][10] - The company emphasizes patient education and conducts health seminars to enhance consumer experience and trust [7] Future Directions - The company plans to focus on three key areas: expanding sales channels, particularly in outpatient markets, enhancing brand influence, and increasing R&D efforts for new product development [12][13] - Continuous optimization of production processes and cost control mechanisms will be prioritized to ensure efficient operations and good returns for shareholders [13] M&A Strategy - The company will consider various directions for mergers and acquisitions, focusing on targets that align with its strategic development, enhance market competitiveness, and enrich its product pipeline [11]